那成人呢?
依據瑞典普查十萬名成人異位性皮膚炎患者的研究，"Comorbidity burden in adult atopic dermatitis：A population‐based study"，發現成人異位性皮膚炎患者如同兒童異位性皮膚炎患者一樣，不只皮膚出狀況，往往會合併其他疾病。
而且當皮膚病況越嚴重，越是如此。
臨床來看，異位性皮膚炎時常合併睡眠障礙、消化問題、氣喘、過敏性鼻炎、身心問題以及社交障礙。
不只治療皮膚，並同步處理多個身體不適，讓皮膚達到從裡到外的改變，正是中醫所擅長的。
有些人認為異位性皮膚炎就是基因的問題，所以無法改變，只能終生壓制症狀。
我認為基因就像種子一樣，我們無法改變基因，但我們可以改變土壤，也就是所謂的「體質」。
當土壤被改變了，就能扭轉種子發芽與否，而不是要終身「治療」。
Atopic dermatitis (AD) is a chronic inflammatory skin disease that has been shown to be associated with allergic comorbidities. However, studies examining comorbidities in patients with AD are incomplete, which may contribute to suboptimal care.
The objective was to compare the risk of developing different allergic and non-allergic comorbidities among adult patients with AD to that of a matched reference cohort in Sweden.
This was a nationwide, population-based cohort study using longitudinal data from primary and specialist care registers. AD patients were identified by confirmed diagnosis in primary or specialist care. A non-AD reference cohort was randomly drawn from the general population and matched 1:1 with the AD patients based on age, gender, and geographical region.
The risk of developing the following conditions was evaluated: asthma, food hypersensitivity, allergic rhinitis, neurological disorders, psychiatric disorders, infections, immunological & inflammatory disorders, type 1 diabetes (T1D), type 2 diabetes (T2D), endocrine & metabolic disorders, skeletal disorders, ocular disorders, cardiovascular diseases, and malignancies.
AD patients are at an increased risk of developing many comorbidities that extend beyond allergic conditions. This study highlights the need for interdisciplinary follow-up of comorbidities in the management of AD patients to reduce overall patient burden.
本篇研究，全文請見這裡，期刊摘要如下：
Background：
Atopic dermatitis (AD) is a chronic inflammatory skin disease that has been shown to be associated with allergic comorbidities. However, studies examining comorbidities in patients with AD are incomplete, which may contribute to suboptimal care.
Objectives：
The objective was to compare the risk of developing different allergic and non-allergic comorbidities among adult patients with AD to that of a matched reference cohort in Sweden.
Methods：
This was a nationwide, population-based cohort study using longitudinal data from primary and specialist care registers. AD patients were identified by confirmed diagnosis in primary or specialist care. A non-AD reference cohort was randomly drawn from the general population and matched 1:1 with the AD patients based on age, gender, and geographical region.
The risk of developing the following conditions was evaluated: asthma, food hypersensitivity, allergic rhinitis, neurological disorders, psychiatric disorders, infections, immunological & inflammatory disorders, type 1 diabetes (T1D), type 2 diabetes (T2D), endocrine & metabolic disorders, skeletal disorders, ocular disorders, cardiovascular diseases, and malignancies.
Results：
This study included 107,774 AD patients [mild-to-moderate (n = 92,413) and severe (n = 15,361)] and an equally sized reference cohort. AD patients displayed a higher risk of developing comorbid conditions for all investigated categories, except for T1D, compared with the reference cohort.
The highest risk compared with the reference cohort was observed for allergic comorbidities, followed by immunological & inflammatory disorders (hazard ratio: 2.15) and infections (hazard ratio: 2.01). Patients with AD also had a higher risk of developing multiple comorbidities (two or more). The risk of comorbidity onset increased alongside AD severity, and patients with active AD were associated with an increased risk of comorbidity onset compared with patients in remission.
Conclusions：
AD patients are at an increased risk of developing many comorbidities that extend beyond allergic conditions. This study highlights the need for interdisciplinary follow-up of comorbidities in the management of AD patients to reduce overall patient burden.
